Annexon, (id:8158 ANNX)
5.14 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 3:28:16 PM)
Exchange closed, opens in 18 hours 1 minutes
About Annexon,
Market Capitalization 576.87M
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
| Headquarters (address) |
1400 Sierra Point Parkway Brisbane 94005 CA United States |
| Phone | 650 822 5500 |
| Website | https://www.annexonbio.com |
| Employees | 71 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ANNX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.27 - 8.40 |
| Market Capitalization | 576.87M |
| P/E trailing | -2.90 |
| P/E forward | -4.79 |
| Price/Book | 1.71 |
| Beta | 1.23 |
| EPS | -1.21 |
| EPS United States (ID:6, base:3402) | 24.22 |